Bread Making: Improving Quality quickly established itself as an essential purchase for baking professionals and researchers in this area. Fully revised and updated and with new chapters on Flour Lipids, and the dietary and nutritional quality of bread, this new edition provides readers with the information they need on the latest developments in bread making science and practice The book opens with two introductory chapters providing an overview of the breadmaking process. Part one focuses on the impacts of wheat and flour quality on bread, covering topics such as wheat chemistry, wheat starch structure, grain quality assessment, milling and wheat breeding. Part two covers dough development and bread ingredients, with chapters on dough aeration and rheology, the use of redox agents and enzymes in breadmaking and water control, among other topics. In part three, the focus shifts to bread sensory quality, shelf life and safety. Topics covered include bread aroma, staling and contamination. Finally, part four looks at particular bread products such as high fiber breads, those made from partially baked and frozen dough and those made from non-wheat flours With its distinguished editor and international team of contributors, Bread Making: Improving Quality, Third Edition, continues to serve as the standard reference for researchers and professionals in the bread industry and all those involved in academic research on breadmaking science and practice.

Theory and Applications of Nonparenteral Nanomedicines presents thoroughly analysed data and results regarding the potential of nanomedicines conceived by diverse non-parenteral routes. In the context of nanotechnology-based approaches, various routes such as oral, pulmonary, transdermal, delivery and local administration of nanomedicine have been utilized for the delivery of nanomedicine. This book discusses the non-parenteral application of nanomedicine, its regulatory implications, application of mucus penetrating nanocarrier, and detailed chapters on development of nanomedicines developed for drug delivery by various route. Beginning with a brief introduction to the non-parenteral delivery of nanomedicine and the safety and regulatory implications of the nanoformulations, further chapters discuss the physiology of the biological barriers, the specificity of the nanocarriers as well as their multiple applications. Theory and Applications of Nonparenteral Nanomedicines helps clinical researchers, researchers working in pharmaceutical industries, graduate students, and anyone working in the development of non-parenteral nanomedicines to understand the recent progress in the design and development of nanoformulations compatible with non-parenteral applications.

Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics provides the interested and informed reader with an overview of current approaches, strategies and considerations relating to the purification, analytics and characterization of therapeutic antibodies and related molecules. While there are obviously other books published in and around this subject area, they seem to be either older (c.a. year 2000 publication date) or are more limited in scope. The book will include an extensive bibliography of the published literature in the respective areas covered. It is not, however, intended to be a how-to methods book.

Harrison analyzes how the U.S. research pharmaceutical industry, faced with domestic political opposition to the prices it charged for prescription drugs, chose to pursue its policy goal of greater appropriability of its intellectual property through the institutions of foreign economic policymaking. As Harrison explains, a new body of literature has developed to analyze the emergence of intellectual property as a major international trade issue. For many researchers, the inclusion of trade related intellectual property (TRIPS) into the Uruguay round of the General Agreement on Tariffs and trade (GATT) negotiations marks an important demonstration of the political influence of U.S. knowledge-intensive industries. However, as he demonstrates, a more thorough specification of the domestic political environment reveals that the research pharmaceutical industry was incapable of achieving its domestic policy objectives at the same time that it is credited with immense international political power. By providing a theory of institutional choice, Harrison reconciles this incongruity. He explains the strategic choices of the research pharmaceutical industry as a function of the transaction costs associated with pursuing its policy objectives within a variety of institutional alternatives. He concludes that he internationalization of intellectual property rights was a result of the changing domestic political environment in which the research pharmaceutical industry found itself the loser in a series of domestic economic policy battles. A thoughtful analysis of particular important to scholars, researchers, and policy makers involved with international trade, intellectual property, the pharmaceutical industry, and public policy.

Farming – whether domestic crops, forestry, fish or livestock – is one of the pillars of human civilization, dating back to the early settlements of Neolithic times. Today, approximately one billion people work the land, providing food and other products for our ever-increasing human population. Arranged geographically, Farming explores the many types of farm and farming that exist today. See how farmers in Malaysia extract milky latex from the bark of rubber trees, used to make everything from protective gloves to vehicle tires; be amazed at the gorgeous stepped rice fields of Bali, where the traditional subak irrigation system is created around ‘water temples’ and managed by Hindu priests; marvel at the vast corn and soya bean fields of Ontario, much of it used for animal feed to support Canada’s beef industry; learn about nomadic pastoralism in low rainfall areas such as Somalia, where herders move camels, cattle, sheep and goats in search of grazing; explore the wineries and vineyards in Bordeaux, where more than 700 million bottles of wine are produced each year by more than 8,500 châteaux; and see how freshwater prawns are harvested for export in the watery deltas of Bangladesh. Presented in a landscape format and with more than 180 outstanding photographs of farming from every part of the planet, Farming offers a pictorial celebration of mankind’s deep connection with the land that sustains us.

The Electronic Health Record: Ethical Considerations analyses the ethical issues that surround the construction, maintenance, storage, use, linkage, manipulation and communication of electronic health records. Its purpose is to provide ethical guidance to formulate and implement policies at the local, national and global level, and to provide the basis for global certification in health information ethics. Electronic health records (EHRs) are increasingly replacing the use of paper-based records in the delivery of health care. They are integral to providing eHealth, telehealth, mHealth and pHealth - all of which are increasingly replacing direct and personal physician-patient interaction - as well as in the developing field of artificial intelligence and expert systems in health care. The book supplements considerations that are raised by national and international regulations dealing with electronic records in general, for instance the General Data Protection Regulation of the European Union. This book is a valuable resource for physicians, health care administrators and workers, IT service providers and several members of biomedical field who are interested in learning more about how to ethically manage health data.

This is an invaluable piece of work that, to my knowledge, is not replicated anywhere, even in piecemeal fashion. It should be read by everyone having a stake in the Transatlantic Trade and Investment Partnership (TTIP) negotiations. It fills an historical vacuum in US-EU agricultural trade relationships that has existed for decades. This book provides the context of the past half century, and it will be invaluable for another half century.' - Clayton Yeutter, Former US Trade Representative, Former US Secretary of Agriculture and Senior Advisor at Hogan Lovells, US Tim Josling and Stefan Tangermann's Transatlantic Food and Agricultural Trade Policy traces the past fifty years of transatlantic trade relations in the area of food and agricultural policy, from early skirmishes over farm policies to on-going conflicts over biotech foods and hormone use in animal rearing. The authors take an analytical approach to the causes of transatlantic conflict and the extent to which these trade tensions in agricultural markets have reflected wide differences in policy approaches and levels of support. They explore the role played by international rules, in the GATT, and subsequently the WTO, in disciplining farm price support policies to allow for more open markets. The book also points to possible ways to end five decades of transatlantic trade tensions in the area of food and farm products. Scholars, practitioners and policymakers will find this timely book an invaluable and comprehensive guide to the causes of, and solutions to, the persistent EU-US trade conflicts in agricultural and food policy.

Now with a new afterword covering the months-long landmark trials of Elizabeth Holmes and Sunny Balwani. ‘I couldn’t put down this thriller . . . the perfect book to read by the fire this winter.’ Bill Gates Winner of the Financial Times/McKinsey Business Book of the Year Award 2018 The riveting true story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup founded by Elizabeth Holmes, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup ‘unicorn’ promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.7 billion. There was just one problem: the technology didn’t work. In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley. ‘Chilling . . . Reads like a West Coast version of All the President’s Men.’ New York Times Book Review